Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What Happened

Key Points

• Pharvaris N.V. shares gapped down to $22.71 from a previous close of $23.18, with the last trading price at $23.33 and a volume of 2,975 shares.
• Analysts have mixed opinions on Pharvaris, with four analysts rating it as a "Buy", one as "Hold", and one as "Sell", leading to an average target price of $34.00.
• The company reported a loss of $0.94 EPS, missing analyst expectations, and is projected to have an annual EPS of -2.71, hinting at ongoing financial challenges.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $23.18, but opened at $22.71. Pharvaris shares last traded at $23.33, with a volume of 2,975 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wedbush reaffirmed an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a research report on Thursday, June 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research report on Saturday, September 27th. Zacks Research raised shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. JMP Securities reduced their target price on shares of Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research note on Wednesday, August 13th. Finally, Guggenheim assumed coverage on shares of Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 target price for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $34.00.

Pharvaris Stock Performance

The business's 50 day moving average price is $22.62 and its two-hundred day moving average price is $18.85. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -6.96 and a beta of -2.77.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07). On average, sell-side analysts expect that Pharvaris N.V. will post -2.71 earnings per share for the current year.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Pharvaris by 30.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock valued at $1,222,000 after purchasing an additional 14,838 shares during the last quarter. Bank of America Corp DE lifted its stake in Pharvaris by 205,286.7% during the fourth quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock valued at $591,000 after purchasing an additional 30,793 shares during the last quarter. TD Asset Management Inc lifted its stake in Pharvaris by 41.5% during the first quarter. TD Asset Management Inc now owns 78,122 shares of the company's stock valued at $1,227,000 after purchasing an additional 22,906 shares during the last quarter. Palumbo Wealth Management LLC lifted its stake in Pharvaris by 38.0% during the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock valued at $221,000 after purchasing an additional 3,881 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company's stock valued at $442,000 after purchasing an additional 10,006 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.